Niclosamide (NIC), an anthelmintic drug, has garnered recent attention for its potential as an antiviral, antibacterial, and chemotherapeutic agent, among other applications. Repurposing NIC presents a current trend, offering significant time and cost savings compared to developing entirely new therapeutic chemical entities. However, its drawback lies in poor solubility, resulting in notably low oral bioavailability. This review consolidates efforts to overcome this limitation by summarizing twelve categories of formulations, spanning derivatives, amorphous solid dispersions, co-crystals, nanocrystals, micelles, nanohybrids, lipid nanoparticles and emulsions, cyclodextrins, polymeric nanoparticles, dry powders for inhalation, 3D printlets, and nanofibers. These formulations cover oral, injectable, inhalable and potentially (trans)dermal routes of administration. Additionally, we present a comprehensive overview of NIC characteristics, including physico-chemical properties, metabolism, safety, and pharmacokinetics. Moreover, we identify gaps in formulation and administration pathways that warrant further investigation to address NIC poor bioavailability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416123PMC
http://dx.doi.org/10.2147/DDDT.S473178DOI Listing

Publication Analysis

Top Keywords

revisiting niclosamide
4
niclosamide formulation
4
formulation approaches
4
approaches pathway
4
pathway drug
4
drug repositioning
4
repositioning niclosamide
4
nic
4
niclosamide nic
4
nic anthelmintic
4

Similar Publications

Niclosamide (NIC), an anthelmintic drug, has garnered recent attention for its potential as an antiviral, antibacterial, and chemotherapeutic agent, among other applications. Repurposing NIC presents a current trend, offering significant time and cost savings compared to developing entirely new therapeutic chemical entities. However, its drawback lies in poor solubility, resulting in notably low oral bioavailability.

View Article and Find Full Text PDF

Mass chemotherapy with niclosamide for the control of : population-based safety profile and treatment effectiveness.

Lancet Reg Health Am

October 2024

Centro de Salud Global, Tumbes, Universidad Peruana Cayetano Heredia, Lima and Tumbes, Perú.

Background: Mass drug administration (MDA) with niclosamide (NSM) can be used to control taeniasis, the cause of neurocysticercosis. NSM is 84.3% effective against taeniasis and is considered safe as it is not absorbed from the intestinal tract.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!